Last reviewed · How we verify
Primovist
At a glance
| Generic name | Primovist |
|---|---|
| Also known as | Gadoxetate disodium, Gd-EoB-DTPA |
| Sponsor | Slawa Cwajna |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment (NA)
- A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer (PHASE2)
- Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis (PHASE4)
- REGULUS: MRI-guided Adaptive SABR for Liver Cancers (PHASE2)
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (PHASE4)
- Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions (NA)
- PET/MRI of Primary Sclerosing Cholangitis
- Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Primovist CI brief — competitive landscape report
- Primovist updates RSS · CI watch RSS
- Slawa Cwajna portfolio CI